About
The U.S. government spends billions of dollars per year on the purchase of drugs making it one of the largest purchasers of pharmaceuticals in the U.S. Sales to the government typically account for a large portion of a company’s total revenue, and a company cannot remain competitive in today’s market without selling to the government. As pharmaceutical manufacturers’ revenue and profits are so closely tied to government contracts and pricing, it is essential to have a thorough understanding of the Veterans Health Care Act, Federal Supply Schedule Contracting, Federal Ceiling Price, and pharmacy benefits programs.
While having the government as a client is lucrative, it can be costly, time consuming and confusing. Understanding the basics and key terms of “Big Four” pricing is necessary to ensure that companies do not enter into price contracts that obligate them to comply with impossible terms. Selling to the VA, DoD, PHS and Coast Guard also requires constant price calculations and price reporting. These calculations are often perplexing and result in price anomalies that can leave even the most seasoned contracting practitioner baffled. On top of complying with the “Big Four’s” numerous rules and regulations, companies must also evaluate how their “Big Four” prices affect their overall pricing.
This publication from ACI’s “Big Four” Pharmaceutical Pricing Boot Camp has been designed to give novices and experienced practitioners alike a complete understanding of core pricing competencies. ACI has assembled a faculty of the government authorities on “Big Four” pricing and pharmacy benefits programs along with expert pricing practitioners. This distinguished faculty will make sense of complicated terminology and pricing calculations and teach you how to navigate the complexities of working with the “Big Four” agencies.
About
The U.S. government spends billions of dollars per year on the purchase of drugs making it one of the largest purchasers of pharmaceuticals in the U.S. Sales to the government typically account for a large portion of a company’s total revenue, and a company cannot remain competitive in today’s market without selling to the government. As pharmaceutical manufacturers’ revenue and profits are so closely tied to government contracts and pricing, it is essential to have a thorough understanding of the Veterans Health Care Act, Federal Supply Schedule Contracting, Federal Ceiling Price, and pharmacy benefits programs.
While having the government as a client is lucrative, it can be costly, time consuming and confusing. Understanding the basics and key terms of “Big Four” pricing is necessary to ensure that companies do not enter into price contracts that obligate them to comply with impossible terms. Selling to the VA, DoD, PHS and Coast Guard also requires constant price calculations and price reporting. These calculations are often perplexing and result in price anomalies that can leave even the most seasoned contracting practitioner baffled. On top of complying with the “Big Four’s” numerous rules and regulations, companies must also evaluate how their “Big Four” prices affect their overall pricing.
This publication from ACI’s “Big Four” Pharmaceutical Pricing Boot Camp has been designed to give novices and experienced practitioners alike a complete understanding of core pricing competencies. ACI has assembled a faculty of the government authorities on “Big Four” pricing and pharmacy benefits programs along with expert pricing practitioners. This distinguished faculty will make sense of complicated terminology and pricing calculations and teach you how to navigate the complexities of working with the “Big Four” agencies.
Contents & Contributors
KNOWING YOUR CUSTOMER: OVERVIEW OF THE “BIG FOUR” AND THEIR PHARMACEUTICAL RELATED PROGRAMS
Marcus Farbstein, Genentech
UNDERSTANDING THE VETERANS HEALTH CARE ACT (VHCA)
Donna Lee Yesner, Mckenna Long & Aldridge LLP
Jennifer Plitsch, Covington & Burling LLP
VHCA § 603: CALCULATING THE NON-FAMP AND THE FEDERAL CEILING PRICE (FCP)
Joy Sturm, Hogan & Hartson LLP
Marci Anderson, VA Office of Inspector General
Melbourne A. Noel, Jr., Department of Veterans Affairs
EXPLORING THE FEDERAL SUPPLY SCHEDULE
Maureen Regan, VA Office of Inspector General
VA MULTIPLE AWARD CONTRACTS
Larry Allen, Coalition for Government Procurement
INTERACTING WITH THE VA AND UNDERSTANDING THE AGENCY’S
STRUCTURE
Marci Anderson, VA Office of Inspector General
EFFECTIVELY MANAGING NEGOTIATIONS WITH V.A.
William W. Goodrich, Jr., Arent Fox LLP
DETERMINING THE FSS PRICE: CONCEPTS AND CONSIDERATIONS IN
GOVERNMENT FSS PROGRAMS
Marci Anderson, VA Office of Inspector General
Maureen Regan, VA Office of Inspector General
Stephen Ruscus, McKenna Long & Aldridge
SINGLE VERSUS DUAL PRICING
Marci Anderson, VA Office of Inspector General
Joy Sturm, Hogan & Hartson, LLP
PHARMACEUTICAL OPERATIONS DIRECTORATE VOLUNTARY
AGREEMENTS FOR RETAIL REFUNDS
Lt. Col. Travis Watson, US Army
OVERVIEW OF THE DEPARTMENT OF DEFENSE (DOD) PHARMACY
PROGRAM
Carol Cooper, TRICARE Management Activity
MANUFACTURER PERSPECTIVES ON TRICARE RETAIL PHARMACY
REBATES
Constance A. Wilkinson, Epstein, Becker & Green, P.C.
340B PROGRAM FUNDAMENTALS
Marcus Farbstein, Genentech
Alice Valder Curran, Hogan & Hartson LLP
William von Oehsen, Safety Net Hospitals for Pharmaceutical Access
STRATEGIES FOR SECURING NATIONAL CONTRACTS AND BLANKET
PURCHASE AGREEMENTS
Larry Allen, Coalition for Government Procurement
“BIG FOUR” PHARMACEUTICAL PRICING BOOT CAMP BRIEFING
Steve Thomas, VA National Acquisition Center
AUDIT RIGHTS, RECORD RETENTION AND PENALTIES
T. Reed Stephens, McDermott Will & Emery LLC
Maureen Regan, VA Office of Inspector General
Publication Details